Clinical & Experimental Cardiology
Open Access

Omega-3 polyunsaturated fatty acids in cardiovascular disease and cancer: A prospective alternative

Joint Conference on 17^th European Heart Disease and Heart Failure Congress and 2^nd International Conference on Cardiovascular Medicine and Cardiac Surgery

March 15-17, 2017 London, UK

Renata Ottes Vasconcelos

Cancer Institute of S�?£o Paulo, Brazil

Posters & Accepted Abstracts: J Clin Exp Cardiolog

Abstract :

Recently, in vitro and in vivo research has demonstrated the beneficial role of omega-3 polyunsaturated fatty acids (omega-3 PUFA) as potential adjuvants for prevention and treatment of many disorders, including cardiovascular disease and cancer. Plenty of works have demonstrated the ability of omega-3 PUFA to exert antitumor activity in different kinds of cancer cells through several mechanisms, including the inhibitory effect on inflammation and cancer cell proliferation, as well as apoptosis induction. Moreover, epidemiological research and clinical interventions have demonstrated that achievable daily doses of omega-3 PUFA are able to decrease the risk of unstable angina, myocardial infarction, and sudden cardiac death, as well as death related to coronary artery disease and heart failure. It is extremely important to establish a relationship between cancer and cardiovascular diseases related to cancer treatments, since, nowadays, it is well-known that several anticancer drugs are cardio toxic, and can cause heart failure. The discussion will focus on the need of a better comprehension of the effects of omega-3 PUFA on the cardiovascular system of cancer patients. Moreover, the most recent results on the beneficial effects of omega-3 PUFA will be reviewed, by particularly focusing on cancer and cardiovascular diseases related to cancer treatments. Results obtained recently by us, and demonstrating the protective role exerted by these fatty acids in normal and malignant melanocytes, will be illustrated. Our results supporting the potential role of omega-3 PUFA as powerful adjuvants in combination with cisplatin will be shown. The need for new and well conducted preclinical studies and clinical interventional trials designed to better explore this research field and answer to many unresolved questions will be discussed.

Biography :

Email: renataottes@yahoo.com.br